Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
April 15, 2024 08:00 ET
|
Optimi Health Corp.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.
Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
August 01, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator...